Mendel Castle-Kirszbaum1, Jeremy Kam2, Yi Yuen Wang3, James King4, Kylie Fryer2, Tony Goldschlager2,5. 1. Department of Neurosurgery, Monash Health, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia. mdck.journal@gmail.com. 2. Department of Neurosurgery, Monash Health, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia. 3. Department of Neurosurgery, St Vincent's Health, Melbourne, Australia. 4. Department of Neurosurgery, Royal Melbourne Hospital, Melbourne, Australia. 5. Department of Surgery, Monash University, Melbourne, Australia.
Abstract
OBJECTIVE: To establish the effect of endoscopic endonasal surgery (EES) on quality-of-life (QoL) in symptomatic Rathke cleft cyst (RCC). METHODS: Analysis of 38 patients with RCC treated by EES, with regular overall (ASBQ-35) and sinonasal-specific (SNOT-22) QoL assessment during the first postoperative year. A systematic literature review of large case series was performed with pooled analysis. RESULTS: In our series, mean age was 53.6 years with a female predominance (73.7%). Larger cysts were seen in males (p < 0.01), those with hypogonadism (p = 0.04), and visual dysfunction (p = 0.04). Complete normalisation of vision was seen in 83.3%. Persistence of visual dysfunction postoperatively was associated with diabetes (p = 0.005), hypertension (p = 0.02), suprasellar only location (p = 0.001), and monocular field cut (p = 0.02). Surgery did not significantly effect hormonal function. Sinonasal QoL transiently worsened after surgery, resolving within 3 weeks. A parallel transient worsening of overall QoL normalised by 6 weeks, and remained at preoperative baseline thereafter. These results were comparable to the literature, where 76.4% demonstrated improvement of vision and 13.1% had recurrence after treatment. There was no significant difference in outcomes between EES and microscopic approaches. CONCLUSIONS: We report longitudinal QoL outcomes in RCC for the first time. Vision commonly improves with surgery, but endocrinopathy is likely to persist. Microvascular risk-factors may compromise visual improvement. Surgery causes a transient worsening of sinonasal symptoms that resolves within 3-6 weeks, but patients may not experience significant improvement in QoL within the first postoperative year.
OBJECTIVE: To establish the effect of endoscopic endonasal surgery (EES) on quality-of-life (QoL) in symptomatic Rathke cleft cyst (RCC). METHODS: Analysis of 38 patients with RCC treated by EES, with regular overall (ASBQ-35) and sinonasal-specific (SNOT-22) QoL assessment during the first postoperative year. A systematic literature review of large case series was performed with pooled analysis. RESULTS: In our series, mean age was 53.6 years with a female predominance (73.7%). Larger cysts were seen in males (p < 0.01), those with hypogonadism (p = 0.04), and visual dysfunction (p = 0.04). Complete normalisation of vision was seen in 83.3%. Persistence of visual dysfunction postoperatively was associated with diabetes (p = 0.005), hypertension (p = 0.02), suprasellar only location (p = 0.001), and monocular field cut (p = 0.02). Surgery did not significantly effect hormonal function. Sinonasal QoL transiently worsened after surgery, resolving within 3 weeks. A parallel transient worsening of overall QoL normalised by 6 weeks, and remained at preoperative baseline thereafter. These results were comparable to the literature, where 76.4% demonstrated improvement of vision and 13.1% had recurrence after treatment. There was no significant difference in outcomes between EES and microscopic approaches. CONCLUSIONS: We report longitudinal QoL outcomes in RCC for the first time. Vision commonly improves with surgery, but endocrinopathy is likely to persist. Microvascular risk-factors may compromise visual improvement. Surgery causes a transient worsening of sinonasal symptoms that resolves within 3-6 weeks, but patients may not experience significant improvement in QoL within the first postoperative year.
Authors: R Trifanescu; V Stavrinides; P Plaha; S Cudlip; J V Byrne; O Ansorge; J A H Wass; N Karavitaki Journal: Eur J Endocrinol Date: 2011-04-18 Impact factor: 6.664
Authors: Joshua L Kennedy; Matthew A Hubbard; Phillip Huyett; James T Patrie; Larry Borish; Spencer C Payne Journal: Ann Allergy Asthma Immunol Date: 2013-07-30 Impact factor: 6.347
Authors: Ronald J Benveniste; Wesley A King; Jane Walsh; Jacob S Lee; Thomas P Naidich; Kalmon D Post Journal: J Neurosurg Date: 2004-10 Impact factor: 5.115
Authors: Daniel Kelberman; Karine Rizzoti; Robin Lovell-Badge; Iain C A F Robinson; Mehul T Dattani Journal: Endocr Rev Date: 2009-10-16 Impact factor: 19.871